Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

INTRODUCTION: The Alzheimer's Disease Research Summits of 2012 and 2015 incorporated experts from academia, industry, and nonprofit organizations to develop new research directions to transform our understanding of Alzheimer's disease (AD) and propel the development of critically needed therapies. In response to their recommendations, big data at multiple levels are being generated and integrated to study network failures in disease. We used metabolomics as a global biochemical approach to identify peripheral metabolic changes in AD patients and correlate them to cerebrospinal fluid pathology markers, imaging features, and cognitive performance. METHODS: Fasting serum samples from the Alzheimer's Disease Neuroimaging Initiative (199 control, 356 mild cognitive impairment, and 175 AD participants) were analyzed using the AbsoluteIDQ-p180 kit. Performance was validated in blinded replicates, and values were medication adjusted. RESULTS: Multivariable-adjusted analyses showed that sphingomyelins and ether-containing phosphatidylcholines were altered in preclinical biomarker-defined AD stages, whereas acylcarnitines and several amines, including the branched-chain amino acid valine and α-aminoadipic acid, changed in symptomatic stages. Several of the analytes showed consistent associations in the Rotterdam, Erasmus Rucphen Family, and Indiana Memory and Aging Studies. Partial correlation networks constructed for Aβ1-42, tau, imaging, and cognitive changes provided initial biochemical insights for disease-related processes. Coexpression networks interconnected key metabolic effectors of disease. DISCUSSION: Metabolomics identified key disease-related metabolic changes and disease-progression-related changes. Defining metabolic changes during AD disease trajectory and its relationship to clinical phenotypes provides a powerful roadmap for drug and biomarker discovery.

Original publication

DOI

10.1016/j.jalz.2017.01.020

Type

Journal article

Journal

Alzheimers Dement

Publication Date

09/2017

Volume

13

Pages

965 - 984

Keywords

Acylcarnitines, Alzheimer's disease, Biochemical networks, Biomarkers, Branched-chain amino acids, Dementia, Metabolism, Metabolomics, Metabonomics, Pharmacometabolomics, Pharmacometabonomics, Phospholipids, Precision medicine, Serum, Sphingomyelins, Systems biology, Aged, Aged, 80 and over, Aging, Alzheimer Disease, Amino Acids, Amyloid beta-Peptides, Aniline Compounds, Cognitive Dysfunction, Cohort Studies, Cross-Sectional Studies, Fasting, Female, Humans, Male, Metabolic Diseases, Metabolic Networks and Pathways, Metabolomics, Peptide Fragments, Phosphatidylcholines, Sphingomyelins, Thiazoles, tau Proteins